Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
20,963 total articles
Kelly Services reported a 10.7% decline in Q1 2026 revenue to $1.0 billion, impacted by weaker demand in certain segments and discrete customer impacts. The company posted a $5.1 million operating loss but an adjusted operating income of $4.1 million. Cost reduction efforts led to a 10.3% decline in SG&A expenses. Kelly affirmed its outlook for gra…
QuasarEdge Acquisition Corporation (NYSE: QRED) has signed a non-binding letter of intent to acquire Robseek Intelligence Inc., an infrastructure platform company focused on AI-driven device distribution and data services primarily in the Middle East. The proposed transaction involves a share-for-share exchange, aiming to bring Robseek public throu…
Evaxion A/S, a clinical-stage TechBio company specializing in AI-based vaccine development, announced its first quarter 2026 financial results alongside key business updates. The company demonstrated strong progress with new data validating their AI-Immunology™ platform’s high precision in cancer vaccine target recognition and scalability in gliobl…
EDAP TMS SA reported strong financial results for Q1 2026, driven by a record $11.6 million in High-Intensity Focused Ultrasound (HIFU) revenue, representing 78% growth year-over-year. The company achieved its seventh consecutive quarter of HIFU revenue growth, with key markets in the U.S. and Europe expanding capital sales of the Focal One Robotic…
Alterity Therapeutics will present significant clinical data and updates on its lead drug ATH434 targeting Multiple System Atrophy (MSA) at several international medical conferences in May 2026. The presentations include promising Phase 2 trial results and plans for a Phase 3 pivotal study, underscoring the company's advancement in developing disea…
Entrada Therapeutics announced positive topline results from Cohort 1 of its ELEVATE-44-201 Phase 1/2 study for Duchenne muscular dystrophy (DMD), demonstrating favorable safety, tolerability, and early functional benefits. The company maintains a strong cash position with $255 million, providing runway into Q3 2027, and plans upcoming data release…
Gilat Satellite Networks Ltd. announced that their CFO, Gil Benyamini, will present and attend the upcoming 21st Annual Needham Technology, Media, & Consumer 1x1 Conference and the 27th Annual Oppenheimer Israel Conference. The company is a leading provider of satellite communications technology and solutions, serving commercial and defense sectors…
Xometry announced record Q1 2026 financial results with 36% revenue growth to $205 million driven by 40% marketplace revenue growth. The company improved Adjusted EBITDA to $10.5 million and expanded active buyers and accounts with significant spend. A strategic partnership with Siemens includes a $50 million equity purchase, reinforcing confidence…
Iovance Biotherapeutics announced robust first quarter 2026 financial results, with total product revenue rising approximately 45% year-over-year to $71 million. The company provided strong guidance for Q2 and full year 2026 revenues, driven primarily by growth in Amtagvi sales. Clinical progress includes a 40% confirmed objective response rate in …
Appian Corporation announced its financial results for Q1 2026, showing significant growth in cloud subscription revenue by 25% year-over-year, total revenue up 21%, and a turnaround to GAAP operating income from a loss in the previous year. The company also raised guidance for 2026, projecting continued double-digit growth in cloud subscriptions a…
Resolute Holdings Management, Inc. reported robust first quarter 2026 financial results, posting a net income per share of $7.19, a substantial improvement from a loss last year. Non-GAAP Fee-Related Earnings per share rose to $0.69, driven by new management agreements and organic fee growth. The company also repurchased $38 million in shares, high…
GPGI, Inc. announced its Q1 2026 results, showing a 3% increase in pro forma adjusted net sales to $421.2 million and record sales growth at CompoSecure driven by the Resolute Operating System (ROS). However, Husky Technologies faced unexpected headwinds from volatile oil and resin prices and tariff uncertainty, resulting in a 16% decline in pro fo…
Invivyd, a US-based biopharmaceutical company focused on antiviral monoclonal antibodies, announced it will hold a webcast conference call on May 14, 2026 to discuss its first quarter financials and provide a corporate update. The company recently received FDA emergency use authorization for a monoclonal antibody targeting SARS-CoV-2, underscoring …
Lifetime Brands, Inc. reported Q1 2026 financial results that beat consensus estimates with 2.4% net sales growth and improved EBITDA, driven by strong performance in Home Solutions and kitchen tools segments. The company implemented early pricing strategies and cost structure actions that are now yielding benefits. Lifetime Brands also commissione…
WW International, Inc. announced its Q1 2026 financial results with total subscribers at 2.7 million and clinical subscribers increasing 46% year-over-year. The company reported $168 million in revenue, with clinical subscription revenue up 32%. WW reaffirmed its full-year 2026 revenue and adjusted EBITDA guidance and announced a fully subscribed d…
Climb Bio, a clinical-stage biotech company focused on immune-mediated diseases, reported its Q1 2026 financials, showing a net loss reduced from last year and a strong cash position bolstered by a recent $110 million private placement. The company provided updates on its two clinical-stage programs—budoprutug and CLYM116—highlighting positive Phas…
Akebia Therapeutics reported Q1 2026 financial results highlighted by a 60% increase in patients treated with Vafseo and Q1 net product revenues of $52.0 million, driven by growing adoption in dialysis-related anemia treatment. The company advanced clinical trials for rare kidney diseases and expects pivotal data for Vafseo dosing regimens by early…
Opus Genetics announced the completion of enrollment in Cohort 1 of its Phase 1/2 clinical trial evaluating OPGx-BEST1 gene therapy for Best Vitelliform Macular Dystrophy (BVMD) and Autosomal-Recessive Bestrophinopathy (ARB). Preliminary safety and early efficacy signals from the initial participant are promising, with topline 3-month data expected…
Widmer Brothers Brewing, a craft beer brand under Tilray Brands, Inc., has launched 'Stay Sunny', a full brand refresh across its Hefeweizen portfolio including new packaging, accessible pack formats, and a multi-month marketing campaign focused in the Pacific Northwest. The refresh introduces two new beers—Hefe Light and Timbers Pils—and emphasize…
Tecnoglass, Inc. (NYSE: TGLS) reported strong first quarter 2026 results with record revenue of $249 million, a 12% increase year-over-year. Despite margin pressure from higher raw material costs and tariffs, net income was $31.9 million and adjusted EBITDA remained robust at $61.5 million. The company expanded its backlog by 19% to $1.36 billion, …
Datadog announced its Q1 2026 financial results showing 32% year-over-year revenue growth to $1.006 billion, positive GAAP operating income, and robust free cash flow of $289 million. The company expanded its AI-driven observability and security platform with several new product launches including MCP Server, Bits AI Security Agent, GPU Monitoring,…
Monte Rosa Therapeutics announced first quarter 2026 financial results along with significant clinical progress across its molecular glue degrader (MGD) pipeline. Key highlights include positive interim data for MRT-8102 showing substantial CRP reductions in patients with elevated cardiovascular risk, preparation to initiate multiple Phase 2 trials…
AI Financial Corporation announced a strategic commercial agreement with SuperQ Quantum Computing Inc. to enhance the security and resilience of its digital asset platform infrastructure using post-quantum cryptography. The partnership will focus on protecting payment, trading, and settlement environments and evaluating infrastructure frameworks fo…
Rapport Therapeutics announces strong first quarter 2026 financial results and positive clinical updates, including sustained seizure reduction in Phase 2a data for RAP-219 in focal onset seizures, accelerated initiation of Phase 3 trials, and a new strategic collaboration with Tenacia Biotechnology for development and commercialization in Greater …
Foghorn Therapeutics reported Q1 2026 financials and corporate progress, highlighting on-track Phase 1 trial for FHD-909 in NSCLC patients with SMARCA4 mutations and compelling preclinical data showing durable tumor regression when combined with anti-PD-1 antibody. The company is advancing selective CBP and EP300 degrader programs targeting breast …
